While tumor genome sequencing has become widely available in clinical and research
settings, the interpretation of tumor somatic variants remains an important bottleneck. Here we …

Antibodies against epidermal growth factor receptor (EGFR)—cetuximab and panitumumab—are
widely used to treat colorectal cancer. Unfortunately, patients eventually develop …

The HER family of transmembrane tyrosine kinase receptors is composed of four members,
HER1 to HER4. HER2 is a ligand-orphan receptor expressed in many human tumors and …

Purpose: Patients with colorectal cancer who respond to the anti-EGFR antibody cetuximab
often develop resistance within several months of initiating therapy. To design new lines of …

Introduction: Translocation of the anaplastic lymphoma kinase (ALK) gene is involved in the
tumorigenesis of a subset of non-small cell lung carcinomas (NSCLCs) and identifies …

Purpose: To investigate whether nuclear factor κB (NF-κB)/interleukin 6 (IL-6) was linked to
docetaxel response in human prostate cancer cell lines, and whether inhibition of NF-κB …

Crosstalk between tumor and stromal cells in the tumor microenvironment alter its properties
in ways that facilitate the invasive behavior of tumor cells. Here, we demonstrate that cancer-…

Anti-HER2 therapies have markedly improved prognosis of HER2-positive breast cancer.
However, different mechanisms play a role in treatment resistance. Here, we identified AXL …

The protein phosphatase 2A (PP2A) is a key tumor suppressor which has emerged as a
novel molecular target in some human cancers. Here, we show that PP2A inhibition is a …

For many patients with breast cancer, symptomatic bone metastases appear after years of
latency. How micrometastatic lesions remain dormant and undetectable before initiating …